Updated results from two Phase III studies, COUGH-1 and COUGH-2, continue to show Merck & Co., Inc.’s investigational agent, gefapixant, significantly reduces the frequency of refractory or unexplained chronic cough, but the purine P2X3 receptor antagonist is also associated with quite a high incidence of taste disturbance, which may limit its promise.
The results were presented at the virtual European Respiratory Society (ERS) congress 2020, and built on interim results presented earlier...